Trichostatin A, a Histone Deacetylase Inhibitor, Potentiated Cytotoxic Effect of ionizing Radiation in Human Head and Neck Cancer Cell Lines
![]() |
Kim, Jin Ho
(Department of Radiation Oncology, Seoul National University College of Medicine)
Shin, Jin Hee (Department of Cancer Research Institute, Seoul National University College of Medicine) Chie, Eui Kyu (Department of Radiation Oncology, Seoul National University College of Medicine) Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University College of Medicine) Kim, Jae Sung (Department of Radiation Oncology, Seoul National University College of Medicine) Kim, Il Han (Department of Radiation Oncology, Seoul National University College of Medicine) Ha, Sung Whan (Department of Radiation Oncology, Seoul National University College of Medicine) Park, Charn Il (Department of Radiation Oncology, Seoul National University College of Medicine) Kang, Wee-Saing (Department of Radiation Oncology, Seoul National University College of Medicine) |
1 | Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002;277:50607-50611 DOI ScienceOn |
2 | Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216 DOI ScienceOn |
3 | Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 1994;214:189-197 DOI ScienceOn |
4 | Fournel M, Trachy-bourget M, Yan PT, et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 2002;62:4325-4330 PUBMED |
5 | Prakash S, Foster BJ, Meyer M, et al. Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 2001;19:1-11 DOI ScienceOn |
6 | Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 2004;59: (in press) |
7 | Vaziri H, Dessain SK, Eaton EN, et al. hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159 DOI ScienceOn |
8 | Schmidt DR, Schreiber SL. Molecular association between ATR and tow components of the nucleosome remodeling and deacetylating complex, HDAC2 and CHD4. Biochem 1999;38:14711-14717 DOI ScienceOn |
9 | Chung YL, Lee YHW, Yen SH, Chi KH. A novel approach for nasopharyngeal carcinoma treatment uses phenyl butyrate as a protein kinase C modulators: implications for radiosensitization and EBV-targeted therapy. Clin Cancer Res 2000;6:1452-1458 PUBMED |
10 | Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002;64:1079-1090 DOI ScienceOn |
11 | Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA. 1999;96:4592-4597 |
12 | Herold C, Ganslmayer M, Ocker M, et al. The histonedeacetylase inhibitor trichostatin A block proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002;36:233-240 PUBMED |
13 | Biade S, Stobbe, CC, Boyd JT, Chapman JD. Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol 2001;77:1033-1042 DOI ScienceOn |
14 | Yoshida M, Beppu T. Reversible arrest of proliferation of Rat 3Y1 fibroblasts in the G1 and G2 phases by Trichostatin A. Exp Cell Res 1988;177:122-131 DOI ScienceOn |
15 | Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001;48(Suppl. 1):20-26 DOI |
16 | Qui L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG. Anti-tumor activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999;80:1252-1258 DOI ScienceOn |
17 | De Ruijter AJM, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg ABP. Histone deacetylase (HDACs): characterization of the classical HDAC family. Biochem J 2003; 307:737-749 |
18 | Kim GD, Choi YH, Dimtchev A, Jeong SJ, Dritschilo A, Jung M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J Biol Chem 1999;274:31127-31130 DOI PUBMED |
19 | McBain JA, Eastman A, Nobel CS, Mueller GC. Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem Pharmacol 1997;53:1357-1368 DOI ScienceOn |
20 | Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer (Abstr.) J Exp Ther Oncol 2002;2:325-332 |
21 | Martinez-Balbas MA, Bauer UM Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000;19:662-671 DOI ScienceOn |
22 | Engelhard HH, Duncan HA, Kim S, Criswell PS, Van Eldik L. Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 model. Neurosurgery 2001;48:616-625 DOI ScienceOn |
23 | Suzuki T, Yokozaki H, Kuniyasu H, et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000;88:992-997 DOI ScienceOn |
24 | Yu X, Guo ZS Marcu MG et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-513 DOI PUBMED |
25 | Saunders N, Dicker A, Popa C, Jones S, Dahler A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res 1999;59:399-404 PUBMED |
26 | Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J Cell Biol 2003;160:1017-1027 DOI ScienceOn |
27 | Juan LJ, Shia WJ, Chen MH, et al. Histone deacetylase specifically down-regulate p53-dependent gene activation. J Biol Chem 2000;275:20436-20433 DOI ScienceOn |
28 | Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002;97:290-296 DOI ScienceOn |
29 | Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62:6108-6115 PUBMED |
30 | Tycko B, Ashkenas J. Epigenetics and its role in disease. J Clin Invest 2000;105:245-246 DOI ScienceOn |
31 | Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylase, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-2868 DOI ScienceOn |
32 | Kim SY, Chu KC, Lee HR, et al. Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol (Stckh) 1997;117:775-784 DOI ScienceOn |
33 | Grunstein M. Histone acetylation and chromatin structure and transcription. Nature 1997;389:349-352 DOI PUBMED ScienceOn |
34 | Yamashita Y, Shimada M, Harimoto N, et al. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/ apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 2003;103:572-576 DOI ScienceOn |
35 | Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-728 PUBMED |
36 | Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet 2003;19:286-293 DOI ScienceOn |
37 | Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997;57:3697-3707 PUBMED |
38 | Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001;7:2292-2300 PUBMED |
39 | Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-8497 PUBMED |
40 | Kim YB, Yoshida M, Sueharu H. Selective induction of cyclin-dependent kinase inhibitors and their roles in cell cycle arrest caused by trichostatin A, an inhibitor of histone deacetylase. Ann N Y Acad Sci 1999;886:200-203 DOI PUBMED |
41 | Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-728 PUBMED |
42 | Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2 (promotes cell survival under stress. Cell 2001;107:137-148 DOI PUBMED ScienceOn |
43 | Chan HM, Kristic-Demonacos M, Smith L, Demonacos C, La Thangue N. Acetylation control of the retinoblastoma tumor-suppressor protein. Nat Cell Biol 2001;3:667-674 DOI ScienceOn |
44 | Luo J, Su F, Chen, D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000;408:377-381 DOI ScienceOn |
![]() |